ALTTO ( Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study
Laufzeit: 01.01.2007 - 31.12.2009
Kurzfassung
BIG2-06/N06D/EGF 106708
A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
